The FTC’s complaint accuses Optum Rx and other pharmacy benefit managers of “abusing their economic power." Optum called the move a "baseless action."

The Federal Trade Commission took action Friday against the three largest pharmacy benefit managers, accusing the companies of “engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price of insulin drugs,

The three price benefit managers jointly administer 80% of all prescriptions in the U.S., the FTC said in the lawsuit.